Jason Robert Pitarresi

This study shows that delivering multiple cytokine and antigen mRNAs via nanoparticles can generate strong anti-tumor immunity against pancreatic cancer in mice.

This study identifies HIF2-driven PTHrP as a cause of cachexia and hypercalcemia in kidney cancer and shows that HIF2 inhibitors can alleviate these symptoms.

This study shows that MYC and p53 alterations in prostate cancer cooperate via VEGF signaling to suppress T cell activity and immunotherapy responses, and that targeting VEGFR2 can enhance immunotherapy efficacy.

This study identifies PTHrP as a driver of pancreatic cancer cachexia by suppressing adipose de novo lipogenesis, showing that blocking PTHrP-PTH1R signaling reduces wasting in mouse models.

This study shows that mitochondrial Ca2+ uptake via MCU promotes pancreatic cancer growth and metastasis by enhancing epithelial plasticity through EMT.

The paper shows hypoxic fibroblasts in pancreas cancer use histone methylation and ROS-mediated NF-κB activation to produce growth factors that drive epithelial-mesenchymal transition in malignant cells.

This paper combines nanoparticle-delivered immune agonists with senescence-inducing agents to enhance T cell responses and control pancreatic cancer in preclinical models.